Formulation Development
Enteris BioPharma to Exhibit at CPhI North America 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned subsidiary of SWK Holdings Corporation…
Hovione & JIXING Announce an Exclusive Global License Agreement for Ophthalmology Program
Hovione, the leader in spray drying and particle engineering, recently announced an exclusive license agreement for a preclinical ophthalmology program, JX08, with….
MoonLake Immunotherapeutics Announces Publication of New Long-Term Disease Control Data From Phase 2b Psoriasis Trial
MoonLake Immunotherapeutics AG recently announced the British Journal of Dermatology (BJD) has published a new data analysis, which can be accessed in the BJD online library, from the Phase 2b clinical trial assessing the effect of sonelokimab….
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination With Atezolizumab in Small Cell Lung Cancer
Imago BioSciences, Inc. recently announced the first participant has been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab (Tencentriq) during…
Lonza & ALSA Ventures Collaborate to Provide Development & Manufacturing Services for Biotech Firms
ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech, and nutrition industries, recently…
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
Entera Bio Ltd. recently announced it recently filed multiple US patent applications to further strengthen the company’s patent protection and support future developments. These patent…
Amphista & Bristol Myers Squibb to Collaborate & Leverage Proprietary Eclipsys Targeted Protein Degradation Platform to Develop Novel Protein Degrading Therapeutics
Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion of the collaboration, as well as royalties on global net sales of products….
WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges
Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered mental status and physical impairments…
WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery
As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….
Adial Pharmaceuticals Announces Research Collaboration With UC San Diego
Adial Pharmaceuticals, Inc. recently announced Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major….
Novartis' Kymriah Receives EC Approval as First CAR-T Cell Therapy for Adults With Relapsed or Refractory Follicular Lymphoma
Novartis recently announced the European Commission (EC) has approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory (r/r)…
Compass Therapeutics Reports Positive Interim Phase 2 Data
Compass Therapeutics, Inc. recently reported additional interim results from a Phase 2 study of CTX-009 in combination with paclitaxel in patients with biliary tract cancers…
EyePoint Pharmaceuticals Announces Expanded License Agreement With Betta Pharmaceuticals
EyePoint Pharmaceuticals, Inc. recently announced the execution of a license agreement with Betta Pharmaceuticals Co. Ltd. to develop and commercialize EYP-1901 in Mainland China, Hong…
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients With Alzheimer’s Disease
BioXcel Therapeutics, Inc. recently announced the first patient has been dosed in the Phase 3 TRANQUILITY II study of BXCL501, the company’s proprietary, orally dissolving…
DepYmed Receives FDA Rare Pediatric Disease & Orphan Drug Designations for its Lead Clinical Candidate for the Treatment of Rett Syndrome
DepYmed Inc. recently announced that the US FDA has granted Rare Pediatric Disease and Orphan Drug designations for its lead clinical candidate, a small molecule…
Hepion Pharmaceuticals Announces Clinical Collaboration With HepQuant in Phase 2b NASH Trial
Hepion Pharmaceuticals, Inc. recently announced it has entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with novel, proprietary investigational technology for…
Lubrizol Life Science Health Launches Innovative Apisolex(TM) Technology to Improve Solubility & Simplify Manufacturing of Parenteral Drug Products
Lubrizol Life Science (LLS) Health, a global leader in accelerating success and innovation in pharmaceutical development, has launched Apisolex, a novel solubility-enhancing excipient for use in….
GLOBAL REPORT – 2021 Global Drug Delivery & Formulation Report: Part 2, Notable Drug Delivery and Formulation Product Approvals and Technologies of 2021
In part 2 of this 3-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on notable drug delivery and formulation product approvals.
ARTIFICIAL INTELLIGENCE - Modernizing Your Clinical Development Safety Practices With Artificial Intelligence
Updesh Dosanjh, MS, says by continuing to explore the ability of these technologies to deliver better and safer treatments, pharmaceutical companies can benefit not only the advancement of the medical community, but the quality of life of patients around the world.
EXECUTIVE INTERVIEW - Adare Pharma Solutions: The Journey to Become a Full-Service Provider
Tom Sellig, CEO at Adare Pharma Solutions, discusses his expectations for Adare and how he can leverage his 30-plus years of pharma experience to put Adare in a competitive position to address complex formulation and development challenges.
